Neo-Healer Trial in HER2-Positive Breast Cancer

Overview

The supplied page description says Harold Burstein, MD, PhD, and Adrienne Waks, MD, discuss the Neo-Healer trial in HER2-positive breast cancer. The transcript provided is empty, so no trial design or findings can be summarized from the supplied material.

Background

Neoadjuvant dual anti-HER2 therapy with chemotherapy is described in the supplied context as the reference approach for stage II–III HER2-positive early breast cancer, with postoperative treatment adapted to residual disease. The context also notes that consensus recommendations favor neoadjuvant therapy for tumors at least 20 mm or with node-positive disease, while some small node-negative tumors may be treated with surgery followed by adjuvant paclitaxel and trastuzumab. Post-neoadjuvant treatment decisions are informed by whether residual invasive disease or pathologic complete response is present. The provided article context does not specify how Neo-Healer relates to these approaches.

Data Highlights

The supplied material contains no transcript or Neo-Healer trial results.

Key Findings

• The supplied page description identifies a discussion by Harold Burstein, MD, PhD, and Adrienne Waks, MD, about the Neo-Healer trial in HER2-positive breast cancer.
• The transcript provided is empty; the supplied material does not describe the trial design or report its results.

Clinical Implications

The supplied material does not provide trial details or results, so it does not support an assessment of Neo-Healer’s efficacy, safety, or relevance to treatment decisions.

Conclusion

The supplied page description identifies a discussion of the Neo-Healer trial in HER2-positive breast cancer. No trial findings are available in the supplied material.

Related Resources & Content

1. Dana-Farber, 2026 -- 2026 ASCO Breast Cancer Highlights: SENOMAC
2. St. Gallen International Breast Cancer Conference, 2025 -- The 19th St. Gallen international breast cancer conference ‘primary therapy of patients with early breast cancer. Evidence, controversies, consensus’: key moments and breakthroughs
3. New England Journal of Medicine, 2025 -- Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
4. uci health — Renowned medical oncologist shares key takeaways from ASCO 2026
5. the asco post — Highlights From the 2021 ASCO Annual Meeting
6. jadpro — Early-Stage Breast Cancer, EGFR-Mutated NSCLC, and High-Risk Melanoma: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner
7. The 19th St. Gallen international breast cancer conference ‘primary therapy of patients with early breast cancer. Evidence, controversies, consensus’: key moments and breakthroughs
8. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
9. Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial | Trials | JAMA Oncology | JAMA Network